US 9,308,183 B2Granted

Therapy for hyperexcitability disorders

AssigneeUCB Pharma S.A.

InventorsCara Heers, Thomas Stoehr, Bettina Beyreuther

Life of this patent

Estimating the term…

Abstract

The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.

Claims20

Dependent claims

A method for alleviating and/or treating a myotonia in a subject in need thereof, comprising administering to the subject lacosamide or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 12/306,953Filed 29 Jun 2007
Priority: EP 0601365530 Jun 2006
Published: US 2010/0324144 A123 Dec 2010
Granted: 12 Apr 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification41 codes

A61K 31/165
Amides, e.g. hydroxamic acids: having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/19
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids: carboxylic acids, e.g. valproic acid
A61K 31/195
Carboxylic acids, e.g. valproic acid: having an amino group
A61K 31/35
Having oxygen as the only ring hetero atom, e.g. fungichromin: having six-membered rings with one oxygen as the only ring hetero atom

Family

US 2010/0324144 A1Pre-grant publication · published 23 Dec 2010
US 9,308,183 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results